Eli Lilly and Company growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: +47.4%
EBITDA: +105.6%
EBIT: +64.3%
EPS: +128.3%
Free cash flow: +1169.5%
Operating cash flow: +119.8%

Forward estimates

Revenue: +15.2%
EBITDA: -20.2%
EPS: +32.7%

Three-year CAGR

Revenue: +31.7%
EBITDA: +47.8%
EBIT: +50.8%
Net income: +49.0%
EPS: +51.8%
Free cash flow: +24.9%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.